Compass Therapeutics (CMPX, Financial) has commenced a new Investigator Sponsored Trial (IST) with the dosing of the first patient to assess tovecimig as a primary treatment for biliary tract cancer (BTC). This trial is being carried out at The University of Texas MD Anderson Cancer Center, marking a notable advancement in BTC treatment strategies.
The study signifies a partnership between Compass and the esteemed medical institution, aiming to explore the potential benefits of tovecimig when used as an initial therapy for BTC patients. This initiative is a part of Compass's broader strategy to combat this challenging cancer type.
Simultaneously, Compass is conducting a second-line Phase 2/3 study of tovecimig, which has already achieved its primary endpoint. The company anticipates sharing additional findings on secondary measures such as progression-free survival and overall survival by the end of the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Compass Therapeutics Inc (CMPX, Financial) is $11.70 with a high estimate of $32.00 and a low estimate of $6.00. The average target implies an upside of 568.57% from the current price of $1.75. More detailed estimate data can be found on the Compass Therapeutics Inc (CMPX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Compass Therapeutics Inc's (CMPX, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
